BTK: a two-faced effector in cancer and tumour suppression

[1]  N. Barlev,et al.  BTK modulates p73 activity to induce apoptosis independently of p53 , 2018, Cell Death Discovery.

[2]  N. Barlev,et al.  BTK blocks the inhibitory effects of MDM2 on p53 activity , 2017, Oncotarget.

[3]  G. Salles,et al.  Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059. , 2017, Blood.

[4]  N. Barlev,et al.  BTK Modulates p53 Activity to Enhance Apoptotic and Senescent Responses. , 2016, Cancer research.

[5]  G. Melino,et al.  The 26S proteasome is a multifaceted target for anti-cancer therapies , 2015, Oncotarget.

[6]  A. Antonov,et al.  Characterization of novel markers of senescence and their prognostic potential in cancer , 2014, Cell Death and Disease.

[7]  Laurens P. Kil,et al.  Targeting Bruton's tyrosine kinase in B cell malignancies , 2014, Nature Reviews Cancer.

[8]  G Melino,et al.  p63 and p73, the ancestors of p53. , 2010, Cold Spring Harbor perspectives in biology.

[9]  E. Candi,et al.  The microRNA and p53 families join forces against cancer , 2010, Cell Death and Differentiation.

[10]  Mauno Vihinen,et al.  Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain , 2009, Immunological reviews.

[11]  L. Honigberg,et al.  Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase , 2007, ChemMedChem.

[12]  D. Durocher,et al.  DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme? , 2001, Current opinion in cell biology.

[13]  J. Kinet,et al.  Activation of BTK by a Phosphorylation Mechanism Initiated by SRC Family Kinases , 1996, Science.

[14]  D. Bentley,et al.  The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases , 1993, Nature.

[15]  W. Gu,et al.  The multiple levels of regulation by p53 ubiquitination , 2010, Cell Death and Differentiation.